Discover
PHVS
Pharvaris N.V.
33.95
2 x 24.85
2 x 42.71
bid
ask
-
0.63
1.82%
2 @ 04:00 PM
33.95 +0.00 (0.00%)
| Ytd | 22.34% | |
| 1y | 96.81% |
33.22
day range
34.58
17.05
52 week range
35.91
| Open | 34.58 | Prev Close | 34.58 | Low | 33.22 | High | 34.58 | Mkt Cap | 2.37B |
| Vol | 374.40K | Avg Vol | 352.43K | EPS | -3.10 | P/E | N/A | Forward P/E | -12.83 |
| Beta | -2.33 | Short Ratio | 3.30 | Inst. Own | 85.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 30.84 | 200-d Avg | 26.87 | 1yr Est | 46.09 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-12 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-04-02 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-12 | 2025-09 | 0 | N/A | 0.08 | 10.26% |
| 2025-11-12 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-12 | 2025-06 | 0 | N/A | -0.07 | -8.05% |
| 2025-08-12 | 2025-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-25 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-05-13 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-04-09 | Wolfe Research | Upgrade | Outperform | |
| 2026-04-07 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-04-06 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-03-09 | RBC Capital | Upgrade | Outperform |
Profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-14 | ABELE STEFAN | Chief Operating Officer | 35.19K | Sale |
| 2026-05-19 | BJORK ELISABETH | Director | 15.17K | Sale |
| 2026-05-14 | GLASSMAN ROBERT R. | Director | 10.50K | Sale |
| 2026-06-24 | LESAGE ANNE PH.D. | Officer | 0.00 | Sale |
| 2026-06-25 | LU PENG M.D., PH.D. | Officer | 65.63K | Sale |
| 2026-06-14 | MODIG BERNDT B.A.E | Chief Executive Officer | 1.09M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | General Atlantic, L.P. | 8.03M | 272.66M | 12.28% |
| 2026-03-30 | FMR, LLC | 6.28M | 213.36M | 9.61% |
| 2026-03-30 | Foresite Capital Management IV, LLC | 4.78M | 162.23M | 7.31% |
| 2026-03-30 | venBio Partners LLC | 4.64M | 157.50M | 7.09% |
| 2026-03-30 | Viking Global Investors, L.P. | 3.65M | 124.03M | 5.59% |
| 2026-03-30 | Eqt Fund Management S.a R.l. | 3.42M | 116.27M | 5.24% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.37M | 46.68M | 2.10% |
| 2026-05-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 800.00K | 27.16M | 1.22% |
| 2026-04-29 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 644.59K | 21.88M | 0.99% |
| 2026-05-30 | Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 500.00K | 16.98M | 0.76% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 397.78K | 13.50M | 0.61% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 338.64K | 11.50M | 0.52% |